Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma
- PMID: 24891451
- PMCID: PMC4201070
- DOI: 10.1093/neuonc/nou098
Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma
Abstract
Background: The impact of adjuvant radiation in patients with atypical meningioma remains poorly defined. We sought to determine the impact of adjuvant radiation therapy in this population.
Methods: We identified 91 patients with World Health Organization grade II (atypical) meningioma managed at Dana-Farber/Brigham and Women's Cancer Center between 1997 and 2011. A propensity score model incorporating age at diagnosis, gender, Karnofsky performance status, tumor location, tumor size, reason for diagnosis, and era of treatment was constructed using logistic regression for the outcome of receipt versus nonreceipt of radiation therapy. Propensity scores were then used as continuous covariates in a Cox proportional hazards model to determine the adjusted impact of adjuvant radiation therapy on both local recurrence and the combined endpoint of use of salvage therapy and death due to progressive meningioma.
Results: The median follow-up in patients without recurrent disease was 4.9 years. After adjustment for pertinent confounding variables, radiation therapy was associated with decreased local recurrence in those undergoing gross total resection (hazard ratio, 0.25; 95% CI, 0.07-0.96; P = .04). No differences in overall survival were seen in patients who did and did not receive radiation therapy.
Conclusion: Patients who have had a gross total resection of an atypical meningioma should be considered for adjuvant radiation therapy given the improvement in local control. Multicenter, prospective trials are required to definitively evaluate the potential impact of radiation therapy on survival in patients with atypical meningioma.
Keywords: atypical meningioma; radiation; recurrence; salvage.
© The Author(s) 2014. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Figures



Similar articles
-
Brachytherapy with surgical resection as salvage treatment for recurrent high-grade meningiomas: a matched cohort study.J Neurooncol. 2020 Jan;146(1):111-120. doi: 10.1007/s11060-019-03342-5. Epub 2019 Nov 19. J Neurooncol. 2020. PMID: 31745706
-
Impact of postoperative radiotherapy on recurrence of primary intracranial atypical meningiomas.J Neurooncol. 2020 Jan;146(2):347-355. doi: 10.1007/s11060-019-03382-x. Epub 2020 Jan 3. J Neurooncol. 2020. PMID: 31900826
-
Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy.J Neurooncol. 2000 Jun;48(2):151-60. doi: 10.1023/a:1006434124794. J Neurooncol. 2000. PMID: 11083080
-
Adjuvant radiotherapy versus observation following gross total resection for atypical meningioma: a systematic review and meta-analysis.Radiat Oncol. 2021 Feb 17;16(1):34. doi: 10.1186/s13014-021-01759-9. Radiat Oncol. 2021. PMID: 33596974 Free PMC article.
-
Role of adjuvant radiotherapy in atypical (WHO grade II) and anaplastic (WHO grade III) meningiomas: a systematic review.Clin Transl Oncol. 2021 Feb;23(2):205-221. doi: 10.1007/s12094-020-02434-3. Epub 2020 Jul 10. Clin Transl Oncol. 2021. PMID: 32651886
Cited by
-
Surgical Management of High-Grade Meningiomas.Cancers (Basel). 2024 May 23;16(11):1978. doi: 10.3390/cancers16111978. Cancers (Basel). 2024. PMID: 38893100 Free PMC article. Review.
-
Overall survival benefit associated with adjuvant radiotherapy in WHO grade II meningioma.Neuro Oncol. 2017 Sep 1;19(9):1263-1270. doi: 10.1093/neuonc/nox007. Neuro Oncol. 2017. PMID: 28371851 Free PMC article.
-
Impact of radiotherapy in atypical meningioma recurrence: literature review.Neurosurg Rev. 2019 Sep;42(3):631-637. doi: 10.1007/s10143-018-0959-8. Epub 2018 Mar 19. Neurosurg Rev. 2019. PMID: 29552691 Review.
-
Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review.BMC Cancer. 2022 Apr 7;22(1):367. doi: 10.1186/s12885-022-09340-7. BMC Cancer. 2022. PMID: 35392834 Free PMC article.
-
Stereotactic radiotherapy as primary definitive or postoperative treatment of intracranial meningioma of WHO grade II and III leads to better disease control than stereotactic radiotherapy of recurrent meningioma.J Neurooncol. 2017 Sep;134(2):407-416. doi: 10.1007/s11060-017-2540-7. Epub 2017 Jun 30. J Neurooncol. 2017. PMID: 28667597
References
-
- Vernooij MW, Ikram MA, Tanghe HL, et al. Incidental findings on brain MRI in the general population. N Engl J Med. 2007;357(18):1821–1828. - PubMed
-
- Goyal LK, Suh JH, Mohan DS, et al. Local control and overall survival in atypical meningioma: a retrospective study. Int J Radiat Oncol Biol Phys. 2000;46(1):57–61. - PubMed
-
- Willis J, Smith C, Ironside JW, et al. The accuracy of meningioma grading: a 10-year retrospective audit. Neuropathol Appl Neurobiol. 2005;31(2):141–149. - PubMed
-
- Combs SE, Schulz-Ertner D, Debus J, et al. Improved correlation of the neuropathologic classification according to adapted World Health Organization classification and outcome after radiotherapy in patients with atypical and anaplastic meningiomas. Int J Radiat Oncol Biol Phys. 2011;81(5):1415–1421. - PubMed
-
- Durand A, Labrousse F, Jouvet A, et al. WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol. 2009;95(3):367–375. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous